Gilead Sciences (NASDAQ:GILD) has been no stranger to controversy, with complaints about the pricing of its hepatitis c therapy Sovaldi coming in from every corner. Even with the drug's massive market success so far ($2.3 billion in sales in its first full quarter on the market), pushback from governments and payers has been a continuing concern for the stock.

And now, with France announcing a new information-sharing agreement among 14 EU countries, that pushback just got a little harder. In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on the news out of Europe.